-
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients with Small-Cell Lung Cancer
Clinical and Translational Science, 2020
-
LOXO-305 in Previously Treated Advanced B-Cell Malignancies
Lancet Oncology, 2020
-
Phase 1 Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
Molecular Cancer Therapeutics, 2020
-
First-in-Human Study of Mivebresib (ABBV- 075), an Oral Pan-Inhibitor of Bromodomain and Extra Tenninal Proteins, in Patients with Relapsed/Refractory Solid Tumors
Clinical Cancer Research, 2019
-
Five-Year Results of a Phase II Trial of Preoperative 5-Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel With Capecitabine (wTX) (With Trastuzumab in HER2-Positive Patients) for Patients With Stage II or III Breast Cancer
Cancer Medicine, 2018
-
Case Report: Immune Checkpoint Inhibitor Elicited Complete Response in a Heavily Pretreated Patient with Metastatic Endometrial Carcinoma with a High Tumor Mutation Burden (TMB)
Molecular Medicine: Current Aspects, 2018
-
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase 1b, Multicenter Study
Cancer Discovery, 2018
-
Assessment of Low Dose Vigil® Engineered Autologous Tumor Cell (EATC) Immunotherapy in Patients with Advanced Solid Tumors
Clinics in Oncology, 2017
-
Case Report: Immune Mediated Complete Response in a Patient with Recurrent Advanced Ewing's Sarcoma (EWS) Following Vigil® Immunotherapy
Journal of Pediatric Hematology/Oncology, 2017
-
Case Report: Vigil Therapy in Pathology Defined High-Risk Differentiated Thyroid Cancer Compounded by Post Ablation High-Risk Factors
Journal of Surgical Oncology and Clinical Research, 2017
-
Case Report: Immune-Mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy
J Pediatric Hematology/Oncology, 2017
-
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma
Molecular Therapy, 2016
-
Phase II Study of Vigil® DNA Engineered Immunotherapy as Maintenance in Advanced Stage Ovarian Cancer
Gynecologic Oncology, 2016
-
Follow-up of bi-shRNAfurin /GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in Patients with Advanced Melanoma
Biomedical Genetics and Genomics, 2016
-
Phase I Trial of bi-shRNA STMNl BIV in Refractory Cancer
Molecular Therapy, 2015
-
Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
Molecular Therapy, 2015
-
Summary of bi-shRNAfuri11/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver
Oncology, 2014
-
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Molecular Therapy, 2013
-
Immune Response and Survival of Refractory Cancer Patients Who Received TGF-P2 Antisense/GM-CSF Gene Modified Autologous Tumor Cell (TAG) Vaccine
Gene Therapy, 2013
-
Long Tem1 Follow Up: Phase I Trial of "bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell" Immunotherapy (FANG™) in Advanced Cancer
Journal of Vaccines & Vaccination, 2013
-
Phase I Trial of "bi shRNA/urin/GMCSF DNA/Autologous Tumor Cell" Vaccine (FANG) in Advanced Cancer
Molecular Therapy, 2012
-
Phase I Trial of TGF-P2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine
Clinical Cancer Research, 2011
-
A Phase II, Single-arm Study of the Anti-a5p I Integrin Antibody Volociximab as Monotherapy in Patients with Platinum-resistant Advanced Epithelial Ovarian or Primary Peritoneal Cancer
Gynecologic Oncology, 2011
-
Induction Oflmmune Responses and Clinical Efficacy in a Phase II Trial ofIDM- 2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 2008
-
Hydatidiform Mole: 25 Years Experience at the Parkland Memorial hospital (PMH)
International Journal of Gynecology and Obstetrics, 2003